AFT PHARMACEUTICALS LIMITED (AFP)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

AFP - AFT PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: March
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 1.24
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.55

20 Dec
2024

0.000

OPEN

$2.55

0.000

HIGH

$2.55

200

LOW

$2.55

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

Last ex-div: 19/06 - (franking ex-di

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx13.8
DPS All xxxxxxxxxxxxxxx1.5
Sales/Revenue xxxxxxxxxxxxxxx181.1 M
Book Value Per Share xxxxxxxxxxxxxxx76.8
Net Operating Cash Flow xxxxxxxxxxxxxxx23.7 M
Net Profit Margin xxxxxxxxxxxxxxx7.99 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx19.43 %
Return on Invested Capital xxxxxxxxxxxxxxx13.75 %
Return on Assets xxxxxxxxxxxxxxx9.98 %
Return on Equity xxxxxxxxxxxxxxx19.43 %
Return on Total Capital xxxxxxxxxxxxxxx20.54 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx22.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx29 M
Total Debt xxxxxxxxxxxxxxx30 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx11 M
Price To Book Value xxxxxxxxxxxxxxx3.74

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx8.8 M
Capex % of Sales xxxxxxxxxxxxxxx4.88 %
Cost of Goods Sold xxxxxxxxxxxxxxx99 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx60 M
Research & Development xxxxxxxxxxxxxxx8 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

03/06/2024

3

Upgrade to Neutral from Underweight

-

-

Both the FY24 earnings (EBIT) result by AFT Pharmaceuticals and FY25 earnings guidance were in line with Jarden's forecasts.

The broker upgrades to Neutral from Underweight on an improved risk/reward balance after expectations were set lower following management's February downgrade. The ratings upgrade is also partly in response to the recent share price decline. 

FY25 earnings growth is underpinned by a margin recovery, and, following management's guidance, Jarden has more confidence the
gross margin can improve from cycling higher impairments and an improving product mix.

Management is also confident the rest-of-the-world (RoW) opportunity is underpinned by US sales and the Hikma Pharmaceuticals relationship.

Hikma and AFT signed an exclusive license and distribution agreement for the commercialisation of Combogesic IV in the US.

The target price rises to NZ$2.90 from NZ$2.80.

FORECAST
Jarden forecasts a full year FY25 dividend of 1.83 cents and EPS of 14.31 cents.
Jarden forecasts a full year FY26 dividend of 2.75 cents and EPS of 17.98 cents.
Access Extra Coverage Research History >

AFP STOCK CHART

FNArena News on AFP

1
Next Week At A Glance – 24-28 Jun 2024

Jun 21 2024 - Weekly Reports
2
Next Week At A Glance – 17-21 – Jun 2024

Jun 14 2024 - Weekly Reports
3
In Case You Missed It – BC Extra Upgrades & Downgrades – 07-06-24

Jun 07 2024 - Weekly Reports
4
Australian Broker Call *Extra* Edition – Jun 03, 2024

Jun 03 2024 - Daily Market Reports
5
Research To Download: Bell Financial, Cash Converters, EML Payments, Freelancer, Qualitas & More

May 29 2024 - FYI

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
2
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
3
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
4
CSL Shares Breaking Free

Jul 23 2024 - Technicals
5
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
6
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
7
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
8
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
9
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
10
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps